Helen Baron, MD
Endocrinology, Diabetes & Metabolism · Rancho Mirage, CANPI 1295762995
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $748,933 of the $957,578 with a category attached, or 78.2%. 18 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 36.0% of the total. Reporting peaked in 2019 at $304,634 and has fallen 53.8% since, to $140,858 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 730 payments — averaging $1311.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$345K
- Novo Nordisk$317K
- Dexcom, Inc.$108K
- AstraZeneca$86K
- Abbott$49K
- Bayer$26K
- plus $26K from 12 others
What the payments were for
- Consulting fees$44,1055%
- Speaking & faculty fees$748,93378%
- Travel & lodging$156,32616%
- Food & beverage$7,6991%
- Education$5150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 151 | $345,154 |
| Novo Nordisk | 275 | $316,687 |
| Dexcom, Inc. | 83 | $107,655 |
| AstraZeneca | 72 | $85,763 |
| Abbott | 73 | $49,493 |
| Bayer | 17 | $26,481 |
| Lilly USA, LLC | 14 | $13,427 |
| Boehringer Ingelheim | 15 | $11,916 |
| BETA Bionics, Inc. | 12 | $636 |
| Tandem Diabetes Care, Inc. | 5 | $106 |
| Insulet Corporation | 4 | $87 |
| Merck | 2 | $37 |
| Radius Health, Inc. | 1 | $30 |
| Cequr Corporation | 2 | $26 |
| Johnson & Johnson | 1 | $23 |
| Companion Medical, Inc. | 1 | $21 |
| Medtronic | 1 | $19 |
| Mannkind Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOUJEO$249,188
- Ozempic$180,049
- RYBELSUS$89,646
- DEXCOM G7 GSS (161)$87,202
- FARXIGA$85,047
- SOLIQUA 100/33$76,266
- FREESTYLE LIBRE 3$48,766
- AMARYL$32,713
- Kerendia$24,667
- JARDIANCE$24,427
- LANTUS$23,344
- DEXCOM STELO GLUCOSE BIOSENSOR$20,858
- DEXCOM G6 TRANSMITTER$19,956
- Tresiba$17,125
- Victoza$6,643
- Xultophy 100/3.6$3,814
- APIDRA$2,026
- iLet Bionic Pancreas$1,157
- iLet Insulin Infusion Kit Inset$386
- iLet Insulin Infusion Kit Contact Detach$386
How this compares
$957,578 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 422 | $594,416 |
| JardianceEmpagliflozin | 165 | $229,590 |
| MounjaroTirzepatide | 137 | $190,833 |
| TrulicityDulaglutide | 130 | $170,185 |
| FarxigaDapagliflozin Propanediol | 103 | $113,719 |
| Tresiba Flextouch U-100Insulin Degludec | 116 | $92,315 |
| JanuviaSitagliptin Phosphate | 72 | $91,283 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 116 | $88,267 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $79,587 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 62 | $59,636 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 36 | $49,006 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 58 | $37,983 |
| KerendiaFinerenone | 21 | $37,408 |
| Humalog Kwikpen U-100Insulin Lispro | 107 | $34,976 |
| Humalog Kwikpen U-200Insulin Lispro | 29 | $34,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $316,687 | $602,479440 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Insulin Lispro | $13,427 | $389,762368 claims |
| Boehringer IngelheimJardiance, Tradjenta | $11,916 | $246,882177 claims |
| AstraZenecaFarxiga | $85,763 | $113,719103 claims |
| MerckJanuvia | $37 | $91,28372 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $345,154 | $49,00636 claims |
| BayerKerendia | $26,481 | $37,40821 claims |
| Johnson & JohnsonInvokana | $23 | $19,21417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Rancho Mirage
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
- Athena Philis-Tsimikasla Jolla$574K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.